期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ijms24076866
关键词
nitric oxide; molsidomine; clozapine; ketamine; schizophrenia; rat
The study aimed to investigate the effectiveness of the NO donor molsidomine in reducing schizophrenia-like impairments caused by NMDA receptor blockade in rats. The results showed that molsidomine attenuated social withdrawal and spatial recognition memory deficits induced by ketamine. Additionally, the combination of molsidomine and clozapine alleviated non-spatial recognition memory deficits. These findings suggest that molsidomine may be a potential adjunctive drug for the therapy of schizophrenia.
The deficiency of the gaseous molecule nitric oxide (NO) seems to be critically involved in the pathogenesis of schizophrenia. Thus, molecules that can normalize NO levels, as are NO donors, might be of utility for the medication of this psychiatric disease. The aim of the present study was to detect the ability of the NO donor molsidomine to reduce schizophrenia-like impairments produced by the blockade of the N-methyl-D-aspartate (NMDA) receptor in rats. Molsidomine's ability to attenuate social withdrawal and spatial recognition memory deficits induced by the NMDA receptor antagonist ketamine were assessed using the social interaction and the object location test, respectively. Further, the efficacy of the combination of sub-effective doses of molsidomine with sub-effective doses of the atypical antipsychotic clozapine in alleviating non-spatial recognition memory deficits was evaluated utilizing the object recognition task. Molsidomine (2 and 4 mg/kg) attenuated social withdrawal and spatial recognition memory deficits induced by ketamine. Co-administration of inactive doses of molsidomine (1 mg/kg) and clozapine (0.1 mg/kg) counteracted delay-dependent and ketamine-induced non-spatial recognition memory deficits. The current findings suggest that molsidomine is sensitive to glutamate hypofunction since it attenuated behavioral impairments in animal models mimicking the negative symptoms and cognitive deficits of schizophrenia. Additionally, the present results support the potential of molsidomine as an adjunctive drug for the therapy of schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据